Early prediction of long-term T-cell reconstitution after HSCT for SCID
Parameter . | Control subjects . | SCID cohort . | P* . | Poor reconstitution . | Good reconstitution . | P† . |
|---|---|---|---|---|---|---|
| Counts of lymphocytes, per μL | ||||||
| Naive CD4+ T cells | 1432 | 341 | < .001‡ | 86 | 630 | .002‡ |
| Memory CD4+ T cells | 303 | 222 | .016‡ | 253 | 185 | .711 |
| Total CD4+ T cells | 1662 | 789 | .001‡ | 451 | 1254 | .003‡ |
| Naive CD8+ T cells | 603 | 300 | .041‡ | 146 | 323 | .153 |
| Memory CD8+ T cells | 150 | 75 | .246 | 69 | 80 | .672 |
| Total CD8+ T cells | 697 | 552 | .412 | 419 | 640 | .328 |
| Total CD19+/CD20+ B cells | 677 | 381 | .059 | 70 | 649 | .005‡ |
| Total CD3-CD16/56+ NK cells | 193 | 127 | .014‡ | 119 | 129 | .625 |
| Ki-67 expression, % | ||||||
| Total CD4+ T cells | 3.0 | 6.1 | .07 | 6.4 | 5.8 | .25 |
| Naive CD4+ T cells | 1.1 | 2.6 | .24 | 3.2 | 2.0 | .27 |
| TRECs | ||||||
| Content in CD4+ T cells, no. per cell | 0.20 | 0.03 | .006‡ | 0.007 | 0.11 | .005‡ |
| Content in CD8+ T cells, no. per cell | 0.10 | 0.04 | .082 | 0.002 | 0.10 | .013‡ |
| No. in CD4+ T cells/μL blood | 410 | 23 | .001‡ | 1.4 | 105 | .002‡ |
| No. in CD8+ T cells/μL blood | 101 | 16 | .039‡ | 0.2 | 51 | .005‡ |
| Telomere length, relative to donor | ||||||
| Naive CD4+ T cells | ND | NA | NA | 1.3 | 1.6 | .079 |
| Memory CD4+ T cells | ND | NA | NA | 1.1 | 1.3 | .240 |
| Other parameters | ||||||
| Age of patient at HSCT, y | NA | 0.7 | 0.4 | 0.7 | .020‡ | |
| Age of donor at HSCT, y | NA | 24.2 | 15.9 | 27.9 | .457 | |
| SCID phenotype, no. | ||||||
| NK- | NA | 9 | 1 | 8 | .007‡ | |
| B- | NA | 6 | 5 | 1 | .025‡ | |
| B cells predominantly of donor origin, no. | NA | 11 | 4 | 7 | .578 | |
| NK cells predominantly of donor origin, no. | NA | 11 | 2 | 9 | .023‡ | |
| Monocytes predominantly of donor origin, no. | NA | 5 | 0 | 5 | .016‡ | |
| Myeloablative conditioning, BU/CY, no. | NA | 11 | 4 | 7 | .578 |
Parameter . | Control subjects . | SCID cohort . | P* . | Poor reconstitution . | Good reconstitution . | P† . |
|---|---|---|---|---|---|---|
| Counts of lymphocytes, per μL | ||||||
| Naive CD4+ T cells | 1432 | 341 | < .001‡ | 86 | 630 | .002‡ |
| Memory CD4+ T cells | 303 | 222 | .016‡ | 253 | 185 | .711 |
| Total CD4+ T cells | 1662 | 789 | .001‡ | 451 | 1254 | .003‡ |
| Naive CD8+ T cells | 603 | 300 | .041‡ | 146 | 323 | .153 |
| Memory CD8+ T cells | 150 | 75 | .246 | 69 | 80 | .672 |
| Total CD8+ T cells | 697 | 552 | .412 | 419 | 640 | .328 |
| Total CD19+/CD20+ B cells | 677 | 381 | .059 | 70 | 649 | .005‡ |
| Total CD3-CD16/56+ NK cells | 193 | 127 | .014‡ | 119 | 129 | .625 |
| Ki-67 expression, % | ||||||
| Total CD4+ T cells | 3.0 | 6.1 | .07 | 6.4 | 5.8 | .25 |
| Naive CD4+ T cells | 1.1 | 2.6 | .24 | 3.2 | 2.0 | .27 |
| TRECs | ||||||
| Content in CD4+ T cells, no. per cell | 0.20 | 0.03 | .006‡ | 0.007 | 0.11 | .005‡ |
| Content in CD8+ T cells, no. per cell | 0.10 | 0.04 | .082 | 0.002 | 0.10 | .013‡ |
| No. in CD4+ T cells/μL blood | 410 | 23 | .001‡ | 1.4 | 105 | .002‡ |
| No. in CD8+ T cells/μL blood | 101 | 16 | .039‡ | 0.2 | 51 | .005‡ |
| Telomere length, relative to donor | ||||||
| Naive CD4+ T cells | ND | NA | NA | 1.3 | 1.6 | .079 |
| Memory CD4+ T cells | ND | NA | NA | 1.1 | 1.3 | .240 |
| Other parameters | ||||||
| Age of patient at HSCT, y | NA | 0.7 | 0.4 | 0.7 | .020‡ | |
| Age of donor at HSCT, y | NA | 24.2 | 15.9 | 27.9 | .457 | |
| SCID phenotype, no. | ||||||
| NK- | NA | 9 | 1 | 8 | .007‡ | |
| B- | NA | 6 | 5 | 1 | .025‡ | |
| B cells predominantly of donor origin, no. | NA | 11 | 4 | 7 | .578 | |
| NK cells predominantly of donor origin, no. | NA | 11 | 2 | 9 | .023‡ | |
| Monocytes predominantly of donor origin, no. | NA | 5 | 0 | 5 | .016‡ | |
| Myeloablative conditioning, BU/CY, no. | NA | 11 | 4 | 7 | .578 |
NK-cell chimerism in the group with poor long-term immune reconstitution was based on 7 patients because hardly any NK cells were present in one of the patients. For the SCID cohort, n = 19; for the group with poor reconstitution, n = 8; for the group with good reconstitution, n = 11.
BU indicates busulphan; CY, cyclophosphamide; ND, not done; NA, not applicable.
Median parameters of the whole SCID cohort at early follow-up (1-4 years after HSCT) were compared with age-matched healthy control subjects.
Within the SCID cohort, median parameters of immunity at early follow-up and HSCT-related variables were compared between the groups of patients with poor and good T-cell reconstitution at late follow-up.
Significant differences in P values.